General Information of Drug Off-Target (DOT) (ID: OTF06CMG)

DOT Name Leucine-rich repeat and transmembrane domain-containing protein 1 (LRTM1)
Gene Name LRTM1
Related Disease
Zimmermann-Laband syndrome ( )
UniProt ID
LRTM1_HUMAN
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Pfam ID
PF13855
Sequence
MKGELLLFSSVIVLLQVVCSCPDKCYCQSSTNFVDCSQQGLAEIPSHLPPQTRTLHLQDN
QIHHLPAFAFRSVPWLMTLNLSNNSLSNLAPGAFHGLQHLQVLNLTQNSLLSLESRLFHS
LPQLRELDLSSNNISHLPTSLGETWENLTILAVQQNQLQQLDRALLESMPSVRLLLLKDN
LWKCNCHLLGLKLWLEKFVYKGGLTDGIICESPDTWKGKDLLRIPHELYQPCPLPAPDPV
SSQAQWPGSAHGVVLRPPENHNAGERELLECELKPKPRPANLRHAIATVIITGVVCGIVC
LMMLAAAIYGCTYAAITAQYHGGPLAQTNDPGKVEEKERFDSSPA

Molecular Interaction Atlas (MIA) of This DOT

1 Disease(s) Related to This DOT
Disease Name Disease ID Evidence Level Mode of Inheritance REF
Zimmermann-Laband syndrome DISXXVYH Disputed Genetic Variation [1]
------------------------------------------------------------------------------------
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DOT
2 Drug(s) Affected the Gene/Protein Processing of This DOT
Drug Name Drug ID Highest Status Interaction REF
Valproate DMCFE9I Approved Valproate affects the expression of Leucine-rich repeat and transmembrane domain-containing protein 1 (LRTM1). [2]
Benzo(a)pyrene DMN7J43 Phase 1 Benzo(a)pyrene increases the expression of Leucine-rich repeat and transmembrane domain-containing protein 1 (LRTM1). [3]
------------------------------------------------------------------------------------

References

1 Candidate loci for Zimmermann-Laband syndrome at 3p14.3.Am J Med Genet A. 2007 Jan 15;143A(2):107-11. doi: 10.1002/ajmg.a.31544.
2 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
3 Benzo[a]pyrene-induced changes in microRNA-mRNA networks. Chem Res Toxicol. 2012 Apr 16;25(4):838-49.